home / stock / nxtc / nxtc news

NXTC News and Press, NextCure Inc. From 11/02/23

Stock Information
Company Name: NextCure Inc.
Stock Symbol: NXTC
Market: NYSE
Website: nextcure.com
Menu
NXTC NXTC Quote NXTC Short NXTC News NXTC Articles NXTC Message Board
Get NXTC Alerts

News, Short Squeeze, Breakout and More Instantly...
NXTC - NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end Cash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-st...
NXTC - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

NXTC - Expected earnings - NextCure Inc.

NextCure Inc. (NXTC) is expected to report $-0.64 for Q3 2023

NXTC - Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of new...
NXTC - NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MA In preclinical testing, NC181 demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and other important findings BELTSVILLE, Md.,...

NXTC - A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed...

NXTC - NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a r...
NXTC - Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Data Presented at the 2023 Military Health System Research Symposium show activity in animal model of acute spinal cord injury-induced immobilization BELTSVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed...

NXTC - NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participat...

NXTC - NextCure GAAP EPS of -$0.64 misses by $0.05

2023-08-03 17:43:36 ET NextCure press release ( NASDAQ: NXTC ): Q2 GAAP EPS of -$0.64 misses by $0.05 . Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million as compared to $159.9 million as of December 31, 2022. The decrease of $29...
Previous 10 Next 10